CellProtect Nordic Pharmaceuticals AB (CPNP) develops innovative new cell therapies to treat severe diseases. The lead program is CellProtect, ex vivo activated and expanded Natural killer (NK) cells for treatment of multiple myeloma. CPNP has established a protocol for expansion and restoration of cytotoxic activity of the NK cells, thereby offering patients a new and potentially curative treatment.
CellProtect is currently in Phase I clinical trials as adjunct treatment to autologous stem cell transplantation in patients with multiple myeloma. The Phase I study is conducted at the Karolinska University Hospital, Huddinge, Sweden.
CPNP is also a partner in the BOOSTB4 study funded through
Horizon2020. BOOSTB4 is a research project which centers on a clinical study with a novel stem cell treatment for the rare, congential disease osteogenesis imperfecta which causes repeated bone fractures and stunted growth.